tirzepatide clinicaltrials.gov Retatrutide vs Tirzepatide: GLP-1, GIP & Glucagon Early‐Onset Obesity and Tirzepatide Treatment:

The mean percentage change in weight at week 72 was 15.0% for the 5-mg dose, 19.5% for the 10-mg dose, and 20.9% for the 15-mg dose, compared to 3.1% for the placebo

SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

This isnt normal for week 2 on 2mg

Bailey SJ, et al

This launch was built around our core beliefs that: People want to be healthy The key to long-term health is to build better habits GLP-1s are powerful meds that make behavior change easier

This might include more frequent blood glucose monitoring (fingerstick or continuous glucose monitoring) and temporary use of short-acting insulin or other antihyperglycemic agents according to their healthcare provider's recommendations